Cookies are small text files held on your computer. Some cookies are required to ensure that the site functions correctly, for this reason we may have already set some cookies. They also allow us to give you the best browsing experience and help us understand how you use our site.
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Let's get started!

Obliterating Data Quality Issues With 10X Greater Accuracy

Get in touch

We will be happy to answer your questions. Let’s create something great together.

Fields marked with an asterisk (*) are required.

Can we stay in touch? If you would like to receive notifications from Adastra on our services, solutions, events and updates, please let us know by clicking the box below. You can unsubscribe from our list at any time.

Adastra prevails under pressure, helping AstraZeneca in a battle against poor data.

Now more than ever, the development of safe and reliable pharmaceuticals is of the utmost importance. As the risk of detrimental illnesses are on the rise, European pharmaceutical and biopharmaceuticals company, AstraZeneca, focusses on scientific research and medicinal advancement, in three important areas:  

  • Cardiovascular, Renal and Metabolic diseases (CVRM)
  • Oncology 
  • Respiratory, Inflammation and Autoimmunity (RIA) 

They are an advocate of science and innovation of medicinal provisions, striving for our global community to achieve healthier living. 

 

The challenge: 

Pharmaceuticals is a booming industry, with substantial emphasis on research and evolving enhancements to technology. But it is also notorious for its competitive edge and that can pose an issue.  Companies in the industry store data to measure brands against a metric system, which are divided into: regions, physicians, demographics, etc. Certain data inputs are consistent across the industry, yet what each organization does with that information can vary. For AstraZeneca, the system utilized to perform specific task was outdated and simply inadequate.  Not to mention the number of individuals who recognized how to access business object universe and manipulate its data for their benefit was at large.  They were in pursuit of an innovative solution that would generate reliable data, which they could manipulate and strategize their decision making towards, targeting physicians and unexploited markets. 

 

Solution searching: 

AstraZeneca believed they had found a resolution through an in-house vendor. To their dismay, the process of developing, designing and implementing the solution had extended their delivery time with minimal progression. They didn’t want to waste anymore. They needed help, fast and from the experts. Adastra had a prior relationship with AstraZeneca and was immediately brought aboard to review the implemented solution and validate its authenticity. Our client dreaded the outcome of our investigation and was further disappointed when we announced the solution was nowhere close to competition; stuck in its initial stages. We knew the onus was on us to pull them from their quandary and so the quest for a new solution was about to commence.   

 

The solution: 

Time was of the essence. Our original solution presented an 8-12-month delivery, reasonable enough to get the job done. To our client, however, it was a waiting game; they needed it in six. The solution required a different strategy.  We received enormous amounts of data and had the gruelling task of analyzing it with achievable scope, but before it could be implemented, it had to be defined. Originally, the data warehouse was platformed on AWS and transitioned onto Redshift, which was a new opportunity for us. We quickly learned the key differences between the two platforms and conversations surrounding scope, definition, attainability and success were being driven.  

Now Adastra is no stranger to constricted timelines. In fact, the opposite can be said. We prevail under pressure. Instead of proceeding with the original plan, we divided each task into phases to ensure completion within 6 months. Transitioning from problem to opportunity. Throughout our data journey, our experts communicated each step of our engagement, providing trustworthy insights with reliable, foolproof results. We offered guidance and suggestions on imperative decisions, which lead to AstraZeneca’s desire to consult us in the future for thought leadership. 

 

Benefits of the solution: 

Our client was thrilled to learn that approximately 175 unique data quality issues had been resolved thanks to Adastra’s solution. The output of the report within the new system versus the legacy system had an accuracy that was 10 times greater. Similar elements from relevant data sources were properly examined and provided clarity and validation. In turn, what became published was the precise number instead of what our client was used to. 

AstraZeneca was impressed and gracious for our honesty and expertise when delivering our alternative strategies for a solution. We shifted from the initial request for a solution that required additional time and costs, to one with a tactical design difference, enabling on-time delivery and cost efficiency with spectacular results. Our client was appreciative of the learning process through their experience with us and by adopting the solution without future modifications, can now propel their business forward.  

Success stories

Updates

© Adastra Corporation. Adastra is a proud member of Adastra Group www.adastragrp.com